Pfizer Inc. will supply almost $22.2 million in drugs to the national medical stockpile to treat patients with Covid-19 and prepare for future emergencies.
The Strategic National Stockpile is purchasing the pharmaceuticals as part of a plan to restructure and resupply, known as SNS 2.0, so that there are enough in the case of future Covid-19 flare-ups.
The contract is for hydromorphone, cisatracurium, Zosyn, cefepime, dobutamine, ondansetron, dopamine, and heparin, according to the notice.
The stockpile previously awarded $81 million in contracts to Fresenius Kabi and Baxter Healthcare Corp. for drugs.
Learn more about Bloomberg Law or Log In to keep reading:
Learn About Bloomberg Law
AI-powered legal analytics, workflow tools and premium legal & business news.
Already a subscriber?
Log in to keep reading or access research tools.